about
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answersIntegrating next-generation sequencing into clinical oncology: strategies, promises and pitfallsNTRK gene fusions as novel targets of cancer therapy across multiple tumour typesPredictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinomaInterventions to improve care coordination between primary healthcare and oncology care providers: a systematic reviewCancer and liver cirrhosis: implications on prognosis and managementChallenge of cancer in the elderlyCan we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an exampleKRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapyRecent advances in the biology of human circulating tumour cells and metastasisTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceCancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015Critically ill patients with cancer: chances and limitations of intensive care medicine-a narrative reviewRecent developments and translational aspects in targeted therapy for metastatic breast cancerUpdate on clinical research and state of the art management of patients with advanced sarcomas and GISTUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsHighlights for ESMO 40: celebration review for lifetime achievement awardsMolecular pathology of cancer: how to communicate with diseaseDiagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyCancer in pregnancy: disentangling treatment modalitiesReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantMechanisms of resistance to EGFR-targeted drugs: lung cancerRenal insufficiency and cancer treatmentsESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO AwardTwenty years of anti-HER2 therapy-associated cardiotoxicityImmune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?Radiological staging in pregnant patients with cancerThreat posed by unproven drugs in medical oncologyAIOM chooses ESMO Open-Cancer Horizons as its official journal: a warm welcome from ESMO Open.Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer.Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.Reply to Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).In the literature: October 2016.Cancer immune cycle: a video introduction to the interaction between cancer and the immune system.Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece.Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.
P1433
Q27928062-28909E93-1AB9-4A5B-9854-9826DD607F02Q28066272-0F6A23A8-FCB7-46EB-85C4-DADB20849842Q28066709-4C92C733-5B7A-4F6A-A16F-80F0CAAEB025Q28066821-940D6078-EEDE-406E-AF24-145485F53612Q28067482-852A787C-F9C4-47BA-8457-E9E8D8798440Q28067650-C8B10011-35F0-471E-B711-C90398770FC1Q28068579-D1FED700-AC4E-482A-95F2-DC56DDDB2B3BQ28069040-93C04CBB-AD48-4135-B7DF-42B1038B7692Q28069620-9D1A4833-AA6D-4FBA-946E-726632340709Q28069764-7C3ABD0D-91D0-43EA-8854-CCF970E209E9Q28070120-9497698D-B7B6-4088-9373-6F8A8591ACF0Q28071772-1D8EE953-432C-42AF-910B-1CCA2AB8349FQ28072071-0C8B73B1-13D1-446C-AD74-873EFBAB989EQ28072563-465686FF-85C4-4642-B53A-1F62A56C1057Q28072755-E8976907-1C86-48E0-9B96-6284913D0AB5Q28073290-66563907-FF05-4409-BE14-EA5D95327970Q28075291-0A76ACEF-71F7-4676-B996-D14A85028889Q28075787-F0887D9C-F30B-469C-B00A-120E894AC4C6Q28076360-4D04F547-C842-48B5-8503-A1B7826FC3C6Q28076646-367FA65D-C8F2-484D-B971-CC9B5694DF3EQ28076763-06CC0BC9-1AD3-470F-A7B9-51F5B9EAF9C9Q28076777-3863A3D4-87A2-412E-80E6-33D46353FAF9Q28077415-4326198B-D52C-42E2-B702-864704E19395Q28079168-A1D7542C-CC0D-45F4-A357-62FF9E6F8C17Q28079204-1440E82D-08C8-44DB-9385-9E2FB79A10F8Q28079391-9A085C2B-7A46-48DB-9631-65FA0416095EQ28079771-2CABB164-17EC-472E-8EC6-F295F58A15B0Q28079904-7A08C24F-013D-4F9C-A30C-83AD48AB4AF1Q29303933-E7CD63A3-AB9D-4599-9F21-49196C0227F3Q53978383-A96D3A4E-D2AF-498D-AEAB-44D486F02902Q53981393-1A8F0A7C-0082-4B49-B1AE-77A258BEC573Q53990140-FF6AAF5E-4392-4F77-9680-BAA780923569Q54001082-4C9ED4A5-C11C-4E03-BFED-21DCACF3BBCBQ54002435-DB8DE5E9-91F4-48E8-9432-62D88E9A95C3Q54023284-4C208CED-1A31-4C1C-98BF-8A4B94BF6F99Q54055141-39816F23-8C72-4587-8F29-CA13532772C4Q54097440-C3FB3508-F879-49F5-9107-BEB26DD411A5Q54116611-C630DAE4-B30A-4196-9D56-0034AE6232B5Q54135887-1E2B9C91-1516-4180-8DE7-C5BA7EC77094Q54143053-3818FB74-7ED9-424E-94EC-9EBAA4CB5F52
P1433
description
czasopismo naukowe
@pl
journal
@en
revista científica
@es
wetenschappelijk tijdschrift van BMJ Group
@nl
wissenschaftliche Fachzeitschrift
@de
name
ESMO Open
@ast
ESMO Open
@en
ESMO Open
@es
ESMO Open
@nl
type
label
ESMO Open
@ast
ESMO Open
@en
ESMO Open
@es
ESMO Open
@nl
prefLabel
ESMO Open
@ast
ESMO Open
@en
ESMO Open
@es
ESMO Open
@nl
P31
P1055
P1156
21100873339